choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Novartis IPO

Novartis IPO Newsletter
  • Fierce Pharma Asia—Pfizer partner's trial win; Roche's $300M China plant; Hengrui's HK IPO plan 16 May 2025 18:00 GMT

    … billion in its Hong Kong IPO. And more. 1. Pfizer … $1.27B in Hong Kong IPO (Morningstar) Jiangsu Hengrui Pharmaceutical, … billion) in a Hong Kong IPO. The plan involves selling … liposome product Onivyde. 6. Novartis cancer drugs Kisqali, Scemblix win …

  • Rx Rundown: Novartis, Abcuro, SpringWorks Therapeutics and more 14 Feb 2025 14:16 GMT

    Deals: Novartis agreed to a deal worth … conducting layoffs ahead of its initial public offering (IPO). Q32 Bio is implementing a … public with a $94 million IPO. Newleos Therapeutics emerged from stealth … part in its $250 million IPO in 2023. Children’s Minnesota …

  • Ascentage prices first biotech IPO of 2025, raising $126M 24 Jan 2025 05:17 GMT

    … the first U.S. initial public offering by a biotechnology company … similar drugs, such as Novartis’ Gleevec and Scemblix, are … Ascentage said in its IPO prospectus. A second Ascentage … outlined IPO plans in January. Overall, however, biotech IPOs have …

  • BioAge Drops Lead Obesity Asset Months After IPO 28 Jan 2025 22:46 GMT

    … million (minus deductions) in an IPO in the last year, noted … . After the windfall from the IPO in September, BioAge’s stock … back on its partnership with Novartis, worth $20 million upfront, to …

  • Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World 25 Jan 2025 00:45 GMT

    … available, such as the Novartis drugs Scemblix and Gleevec. … therapies, Ascentage said in its IPO filing. Furthermore, first- and … cancers developed resistance to the Novartis drugs. “In a five … period,” Ascentage said in the IPO filing. “Therefore, we believe …

  • 2024: A Year of Cautious IPOs, Restraint and Breakthroughs 18 Dec 2024 14:52 GMT

    … knew the answer: IPOs. Everything was IPOs all the time. Fewer … following the pandemic’s IPO boom. Will the window … favorite buyout of 2024 was Novartis’ acquisition of neuromuscular disease … still in preclinical development. Novartis’ interest in the company …

  • Adlai Nortye Ltd. Announces Closing of Initial Public Offering 03 Oct 2023 16:05 GMT

    … closing of its previously announced initial public offering of 2,500,000 American … companies such as Eisai and Novartis, to fully realize the potential … with respect to the proposed initial public offering and the concurrent private placement …

  • Swiss pharma giant Novartis says 30 pipeline drugs with ‘significant potential’ will drive long-term growth 21 Nov 2024 13:00 GMT

    Swiss pharmaceutical giant Novartis on Thursday lifted its … between 2024 and 2030. “Novartis has completed its transformation into … in 2023, also through an IPO. Such moves have seen the … neuroscience and oncology. Shares in Novartis edged ahead 0.3 percent …

  • Adlai Nortye Ltd. Announces Pricing of Initial Public Offering 29 Sep 2023 06:46 GMT

    … announced the pricing of its initial public offering of 2,500,000 American … companies such as Eisai and Novartis, to fully realize the potential … with respect to the proposed initial public offering and the concurrent private placement …

  • Novartis Slumps On Lagging Sales Of Its Biggest Moneymaker 29 Oct 2024 14:17 GMT

    … .92, according to MarketSurge. Novartis stock is also losing support … were expecting one." Novartis put up several strong numbers … -double-digit percentage. Previously, Novartis guided sales to high-single … To Buy And Watch: Top IPOs, Big And Small Caps, …

Satisfied with the content?

Continue to create your account.